Tango Therapeutics, Inc.
TNGX US87583X1090
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -4% | -34% | 35% | -69% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Beckman Daniella CFO |
3.16 USD |
3,948 Sold |
12,481 USD |
04/02/2025 | 05/02/2025 |
| Barry Douglas SR OFF |
3.16 USD |
2,556 Sold |
8,081 USD |
04/02/2025 | 05/02/2025 |
| Crystal Adam O |
3.16 USD |
6,851 Sold |
21,659 USD |
04/02/2025 | 05/02/2025 |
| Weber Barbara CEO |
3.16 USD |
9,013 Sold |
28,494 USD |
04/02/2025 | 05/02/2025 |
| Weber Barbara CEO |
2.99 USD |
9,778 Sold |
29,217 USD |
04/02/2025 | 04/02/2025 |
| Crystal Adam O |
2.99 USD |
7,432 Sold |
22,207 USD |
04/02/2025 | 04/02/2025 |
| Barry Douglas SR OFF |
2.99 USD |
2,774 Sold |
8,289 USD |
04/02/2025 | 04/02/2025 |
| Beckman Daniella CFO |
2.99 USD |
4,284 Sold |
12,801 USD |
04/02/2025 | 04/02/2025 |
| Rothenberg Mace |
3.78 USD |
10,000 Bought |
37,800 USD |
14/11/2024 | 18/11/2024 |
| Rothenberg Mace |
3.62 USD |
10,000 Bought |
36,200 USD |
14/11/2024 | 14/11/2024 |